Bamosiran clinical trials
Also written SYL040012.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses bamosiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SYL040012
- 3
Studies by the year they started
4 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses bamosiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- SYL040012, Treatment for Open Angle GlaucomaCompletedPhase 2Sylentis, S.A.NCT02250612Written as 1 drop of 0.375% SYL040012 (bamosiran)How we know
- Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle GlaucomaCompletedPhase 2Sylentis, S.A.NCT01739244Written as SYL040012How we know
- SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm HgCompletedPhase 1/2Sylentis, S.A.NCT01227291Written as SYL040012How we know
- Tolerance and Effect on Intraocular Pressure After Administration of SYL040012CompletedPhase 1Sylentis, S.A.NCT00990743Written as SYL040012How we know
Codes
What other systems call bamosiran · ClinicalTrials.gg INT016198
- UNII (FDA) C8Q2RMU41OBAMOSIRANOne source FDA
- NCI Thesaurus C171793BamosiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C8Q2RMU41O | BAMOSIRAN | One source FDA |
| NCI Thesaurus | C171793 | Bamosiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.